InspireMD

Company Overview

Snapshot

Founded in April 2005, InspireMD operates with 51–200 employees and has raised a total of $229.48 million across 11 funding rounds from 5 investors. In August 2025, the company secured a significant financing round with participation from OrbiMed and Marshall Wace.

Business overview

InspireMD is a commercial-stage medical device company specializing in proprietary stent designs with integrated embolic prevention systems (EPS). Its core technology, MicroNet mesh, addresses the shortcomings of conventional carotid stenting and surgery, providing neurovascular protection and stroke prevention. The company aims to establish its MicroNet technology as the industry standard for sustained embolic protection and is expanding its portfolio to include applications in peripheral artery procedures, serving the healthcare and medical device sectors.

Strategic signal

In October 2024, InspireMD announced the approval of its Investigational Device Exemption (IDE) application for the CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System. This regulatory milestone signals significant progress towards potential U.S. market entry and commercialization of its advanced carotid stent technology, indicating a strong focus on expanding its product reach and validating its innovative solutions in neurovascular protection.

Company Intelligence Q&A

What was a key strategic development for InspireMD in late 2025?

In November 2025, InspireMD appointed Peter A. Soukas, M.D., as Chief Medical Officer, a strategic move to strengthen its medical leadership as it advances its product pipeline and commercial initiatives.

What is InspireMD's recent progress with its CGuard Prime Carotid Stent System?

In October 2024, InspireMD announced the approval of its Investigational Device Exemption (IDE) application for the CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System, a critical step towards U.S. regulatory approval.

What was a significant corporate announcement by InspireMD in October 2024?

In October 2024, InspireMD announced the establishment of its global headquarters in Miami, Florida, to support the anticipated U.S. launch and commercialization of the CGuard Prime Carotid Stent System.

What was a notable financing event for InspireMD in 2025?

In August 2025, InspireMD secured a financing round with participation from OrbiMed and Marshall Wace, contributing to its total capital raised.

What was a key regulatory submission for InspireMD in September 2024?

In September 2024, InspireMD announced the submission of a Premarket Approval Application to the FDA, seeking U.S. regulatory approval of the CGuard™ Prime Carotid Stent System.